Decreased glucagon-like peptide 1 receptor expression in endothelial and smooth muscle cells in diabetic db/db mice: TCF7L2 is a possible regulator of the vascular glucagon-like peptide 1 receptor.
Kimura, Tomohiko; Obata, Atsushi; Shimoda, Masashi; Okauchi, Seizo; Hirukawa, Hidenori; Kohara, Kenji; Kinoshita, Tomoe; Nogami, Yuka; Nakanishi, Shuhei; Mune, Tomoatsu; Kaku, Kohei; Kaneto, Hideaki.
Diab Vasc Dis Res
; 14(6): 540-548, 2017 11.
Artigo em Inglês | MEDLINE | ID: mdl-28830217
Diabetes risk gene and Wnt effector Tcf7l2/TCF4 controls hepatic response to perinatal and adult metabolic demand.
Selective disruption of Tcf7l2 in the pancreatic ß cell impairs secretory function and lowers ß cell mass.
Lineage regulators direct BMP and Wnt pathways to cell-specific programs during differentiation and regeneration.
Decreased TCF7L2 protein levels in type 2 diabetes mellitus correlate with downregulation of GIP- and GLP-1 receptors and impaired beta-cell function.
The Extracellular Surface of the GLP-1 Receptor Is a Molecular Trigger for Biased Agonism.
Phase-plate cryo-EM structure of a biased agonist-bound human GLP-1 receptor-Gs complex.
Transcription factor-associated combinatorial epigenetic pattern reveals higher transcriptional activity of TCF7L2-regulated intragenic enhancers.
Modulation of Glucagon Receptor Pharmacology by Receptor Activity-modifying Protein-2 (RAMP2).
Crystal structure of the GLP-1 receptor bound to a peptide agonist.
Nonconventional glucagon and GLP-1 receptor agonist and antagonist interplay at the GLP-1 receptor revealed in high-throughput FRET assays for cAMP.